Navigation Links
NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
Date:8/5/2008

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, will hold a conference call hosted by Mr. David Allan, Chairman and CEO, at 12:00pm EDT today, August 5, where members of the professional investment community are invited to discuss the preliminary results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC) with management.

CONFERENCE CALL DETAILS

DATE: August 5, 2008

TIME: 12:00 PM Eastern Time

DIAL IN NUMBER: 416 644 3419 and 1 800 731 5774

A live audio webcast of the conference call will be available at http://www.ymbiosciences.com.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. In addition to nimotuzumab, the Company is developing AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF- will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
2. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
3. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
4. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
5. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
6. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
7. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
8. Notice of Conference Call and Webcast
9. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
10. Healthcare Technologies, Ltd. Receives Notice From Nasdaq
11. Tapestry Receives Notice Regarding Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... A luxury car manufacturer ... popular corporate team building events this summer. , Each team gathered ... competition to whet their palettes. Three teams were then formed, and each ...
(Date:7/27/2017)... RESEARCH TRIANGLE PARK, N.C., July 27, 2017 ... today announced its financial results for the second ... "Our second quarter total net revenues ... level ever," said Martine Rothblatt, Ph.D., United Therapeutics ... believe that Orenitram is well-positioned given the large ...
(Date:7/26/2017)... ... 2017 , ... CardioWise, Inc. , is pleased to ... analysis software, and an associated pending patent from Johns Hopkins Technology Ventures through ... uses high resolution cardiac CT to analyze cardiac wall motion that provides extraordinary ...
(Date:7/26/2017)... ... July 26, 2017 , ... Franz ... Semantic Graph Database technology for Knowledge Graphs, today announced Gruff v7.0 , ... Gruff provides novice users and graph experts the ability to visually build queries ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):